A practical method to determine the "atherogenic lipoprotein phenotype"

Archives of Medical Science

Volumn 4, Issue 2, 2008, Pages 215-217

  Rizzo, Manfredi ^a   Rini, Giovam Battista ^a   Spinas, Giatgen A ^b   Berneis, Kaspar ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; ARTERY DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DENSITY GRADIENT CENTRIFUGATION; DYSLIPIDEMIA; ELECTRON MICROSCOPY; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LETTER; LIPID BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; REPRODUCIBILITY;

EID: 48249114712     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. Rizzo M, Berneis K. Low-density lipoproteins size and cardiovascular risk assessment. QJM 2006; 99: 1-14.
2. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
3. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046-51.
4. Wyszynski DF, Waterworth DM, Barter PJ, et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol 2005; 95: 194-8.
5. Wilkinson P, Leach C, Ah-Sing EE, et al. Influence of alpha-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Atherosclerosis 2005; 181: 115-24.
6. März W, Scharnagl H, Abletshauser C, et al. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 2001; 103: 1942-8.
7. Krauss R, Burke D. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23: 97-104.
8. Rizzo M, Trepp R, Berneis K, Christ ER. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. Eur J Endocrinol 2007; 156: 361-7.
9. Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 186-9.
10. Rizzo M, Pernice V, Frasheri A, Berneis K. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis 2008; 197: 237-41.
11. Kalogirou M, Tsimihodimos V, Saougos V, Lagos K, Tselepis AD, Elisaf M. Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pre-treatment. Arch Med Sci 2007; 3: 344-50.